Block, Inc. launched its first major Bitcoin consumer campaign on October 1, 2026, targeting 60 million Americans curious about Bitcoin. The campaign promotes Bitcoin as everyday money, emphasizing its capped supply and decentralized nature, rather than a speculative asset. This follows Block's earlier efforts to ease Bitcoin tax reporting and expand merchant acceptance through Square and Cash App. The campaign aims to boost consumer demand to match the growing merchant supply, with future developments to watch including user activity on Cash App, merchant uptake, and potential tax rule changes in Washington.
Block's Bitcoin consumer campaign is current as of Oct 02, 2026 02:41 WIB. For readers following cryptocurrency markets, here is Pluang's snapshot: of 50 major cryptocurrencies priced today, 30 rose and 19 fell. Notable movers include Compound (COMP) at Rp429.188 with a 1-day change of -3.45% and a typical hold time on Pluang of 97 days, SushiSwap (SUSHI) at Rp4.710 with -3.14%, and Theta Network (THETA) at Rp3.930 with -3.06%.
The global music market is projected to grow from $36.13 billion in 2026 to $57.74 billion by 2032, at a CAGR of 8.07%, fueled by paid streaming subscriptions, smartphone adoption, and digital music discovery. North America remains the largest market...
Ethlabs, an independent nonprofit research group focused on Ethereum, announced that Ethereum co-founder Mihai Alisie has joined as an anchor funder. Alongside Payward, Gattaca HQ, and 19 other Ethereum community supporters, Ethlabs aims to promote t...
BNB Chain has launched its Jenner hard fork on the BNB Smart Chain testnet, introducing new features such as Payment Lane, which reserves 5% of each block's gas capacity for eligible payments. The upgrade also enables smart contracts to access block ...
Ethereum's draft proposal EIP-8450 introduces a post-quantum public-key registry for validators, aiming to improve security against quantum computing threats. The design incorporates hash-based cryptography methods like leanXMSS keys and VRF tree roo...
HUTCHMED announced that the US FDA has granted orphan drug designation to sovleplenib for treating primary immune thrombocytopenia (ITP), a rare autoimmune disorder causing low platelet counts and bleeding risks. This status provides benefits like 7 ...
